A Phase 3 interventional study of insulin degludec/insulin aspart and insulin degludec/insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 45 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-02.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 44th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 31st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 186th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 318th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe and the United States of America (USA).
The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart (IDeg/IAsp) in subjects with type 2 diabetes mellitus previously treated with insulin glargine.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 272 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart
Drug: insulin degludec/insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
Also known as: IDegAsp
Drug pages: Insulin degludec · Insulin Aspart
Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
Also known as: IDegAsp
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)
Change from baseline in HbA1c after 26 weeks of treatment.
Time frame: Week 0, Week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment
Time frame: Week 0, Week 26
Subjects With HbA1c Below 7.0%
Number of subjects with HbA1c below 7% after 26 weeks of treatment.
Time frame: Week 26
Percentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia
Percentage of subjects with HbA1c below 7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.
Time frame: Week 26
Incidence of Treatment Emergent Adverse Events (TEAEs)
A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
Time frame: Weeks 0-28
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Weeks 0-27
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period
Confirmed hypoglycaemic episodes in the maintenance period (from Week 16 to the end of the trial including follow-up \[Week 27\]) consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: From week 16 to end of trial including follow-up (week 27)
Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes
Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.
Time frame: Weeks 0-27
The trial was conducted in 43 sites in 5 countries: Algeria (3 sites), Germany (5 sites), Malaysia (3 sites), Turkey (3 sites), and United States (29 sites).
| Milestone | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Started | 136 | 136 |
| Exposed | 135 | 134 |
| Completed | 115 | 119 |
| Not completed | 21 | 17 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Unclassified | 18 | 15 |
Change from baseline in HbA1c after 26 weeks of treatment.
| Percent (%) glycosylated haemoglobin | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) | -1.45 ± 0.09 | -1.33 ± 0.09 |
Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment
| mmol/L | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -1.68 ± 0.23 | -1.98 ± 0.23 |
Number of subjects with HbA1c below 7% after 26 weeks of treatment.
| Subjects | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Subjects With HbA1c Below 7.0% | 91 | 85 |
Percentage of subjects with HbA1c below 7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.
| percentage of subjects | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Percentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia | 25.4 | 32.0 |
A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
| number of events | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) | 242 | 286 |
Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
| episodes | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes | 552 | 323 |
Confirmed hypoglycaemic episodes in the maintenance period (from Week 16 to the end of the trial including follow-up \[Week 27\]) consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
| episodes | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period | 230 | 143 |
Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.
| episodes | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes | 82 | 49 |
Collected over The adverse events were collected from week 0 to Week 28.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegAsp Simple | — | 7/135 (5.2%) | 45/135 (33.3%) |
| IDegAsp Step Wise | — | 10/134 (7.5%) | 53/134 (39.6%) |
| Event | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 2/135 | 0/134 |
| Acute coronary syndromeCardiac disorders | 0/135 | 1/134 |
| Aortic valve stenosisCardiac disorders | 0/135 | 1/134 |
| Coronary artery diseaseCardiac disorders | 1/135 | 1/134 |
| Coronary artery occlusionCardiac disorders | 0/135 | 1/134 |
| Ventricular fibrillationCardiac disorders | 0/135 | 1/134 |
| Abdominal pain lowerGastrointestinal disorders | 0/135 | 1/134 |
| HaemorrhoidsGastrointestinal disorders | 0/135 | 1/134 |
| Pancreatitis acuteGastrointestinal disorders | 0/135 | 1/134 |
| Ischaemic strokeNervous system disorders | 0/135 | 1/134 |
| Event | IDegAsp Simple | IDegAsp Step Wise |
|---|---|---|
| NasopharyngitisInfections and infestations | 12/135 | 20/134 |
| Upper respiratory tract infectionInfections and infestations | 14/135 | 10/134 |
| InfluenzaInfections and infestations | 5/135 | 12/134 |
| HeadacheNervous system disorders | 9/135 | 8/134 |
| DiarrhoeaGastrointestinal disorders | 5/135 | 8/134 |
| Back painMusculoskeletal and connective tissue disorders | 6/135 | 8/134 |
| BronchitisInfections and infestations | 6/135 | 7/134 |
| Age, Continuous(years) | IDegAsp Simple | IDegAsp Step Wise | Total |
|---|---|---|---|
| Mean | 58.8 ± 9.8 | 59.1 ± 9.4 | 58.9 ± 9.6 |
| Sex: Female, Male(Participants) | IDegAsp Simple | IDegAsp Step Wise | Total |
|---|---|---|---|
| Female | 60 | 53 | 113 |
| Male | 76 | 83 | 159 |
| Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDegAsp Simple | IDegAsp Step Wise | Total |
|---|---|---|---|
| Mean | 8.2 ± 0.9 | 8.2 ± 0.9 | 8.2 ± 0.9 |
| Fasting plasma glucose(mmol/L) | IDegAsp Simple | IDegAsp Step Wise | Total |
|---|---|---|---|
| Mean | 7.8 ± 2.3 | 8.1 ± 3.0 | 8.0 ± 2.6 |
Ran from Aug 2012 to primary completion in Aug 2013, 11 months.
Results were first posted in Nov 2015, 2 years 2 months after primary completion. A results delay was requested in Nov 2013.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart